Navigation Links
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
Date:11/20/2007

Ph.D., Executive Vice President, Chief Scientific Officer and President, Research and Development, Bristol-Myers Squibb. "This approval is a reflection of our ongoing commitment to provide innovative therapies, such as ABILIFY, to help adults living with depression."

"We are pleased that ABILIFY has achieved this important milestone as the first medication approved as adjunctive treatment for adults with major depressive disorder," said Taro Iwamoto, Ph.D., Chief Executive Officer, President and Chief Operating Officer, Otsuka Pharmaceutical Development and Commercialization, Inc. "This new add-on treatment option for depression represents hope for many adults suffering from this debilitating illness."

Major depressive disorder affects millions of U.S. adults at some point in their lives.(2) A recent study evaluated different treatment approaches, including adjunctive medications and switching strategies, in patients with MDD.(1) The study found that 63 percent of patients did not achieve adequate relief of depressive symptoms following the initial treatment with an antidepressant alone.(1) Additionally, the study demonstrated that the use of adjunctive medications in treatment may be useful to improve unresolved depressive symptoms.(1)

Clinical Trial Design and Findings

Two six-week, double-blind, randomized, placebo-controlled, multicenter studies evaluated the efficacy and safety of add-on ABILIFY in adult patients with a primary diagnosis of major depressive disorder who had experienced an inadequate response to prior antidepressant therapy (one to three courses) in the current episode.

After an eight-week prospective treatment phase with one ADT plus single- blind placebo to confirm inadequate response to ADT, 743 participants entered a six-week randomized treatment phase during which they continued their ADT plus double-blind adjunctive placebo or adjunctive ABILIFY. All study participants received one of the commonly prescribed
'/>"/>

SOURCE Bristol-Myers Squibb Company and Otsuka PharmaceuticalCo., Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Bioscrypts V-Station MIFARE Placed on Transportation Security Administrations Qualified Products List
3. Australian Therapeutics Goods Administration Approval for ActiPatch Achieved
4. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
5. Korean Food and Drug Administration Approval for ActiPatch Achieved
6. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
7. FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
8. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
9. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
10. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
11. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... The wet ... use of special anti-vascular endothelial growth factor agents given by injection into the ... not have a scientific protocol for the many millions diagnosed with it. AMD ...
(Date:9/2/2015)... -- Biovista Inc. is glad to announce ... science challenge, a global competition hosted by the Rare ... the latest life science innovations and technologies. ... capability to support Steven Laffoon and his ... Niemann-Pick Disease Type A (NPA), a rare and fatal ...
(Date:9/2/2015)... -- Aytu BioScience, Inc. (OTCQB: AYTU), a specialty healthcare ... conditions, announced today that it has closed the final ... raising a total of $5.175 million, which includes proceeds ... Josh Disbrow , Chief Executive Officer of ... to be used to conduct clinical studies for both ...
(Date:9/2/2015)... , September 2, 2015 ... des Wettbewerbs BeHEARD von 2015 bekanntgeben zu können. ... Rare Genomics Institute. Biovista unterstützt mit ... für die Behandlung anderer Krankheiten als denen, für ... Laffoon und sein Team bei der Wylder ...
Breaking Biology Technology:StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2
... CHENGDU, China, Oct. 1, 2011 /PRNewswire-Asia-FirstCall/ -- ... or the "Company"), a pharmaceutical company that ... Chinese medicine, branded generics and active pharmaceutical ... of the manufacturing environmental assessment at its ...
... 2011 Life Technologies Corporation (NASDAQ: ... detailing key steps of the Ion PGM™ sequencer ... at the core of Ion semiconductor sequencing are now openly ... as well as scientists that are closely watching the growth ...
... , Troy, N.Y. Waste heat is a byproduct ... driving a car to flying an aircraft or operating ... have developed new nanomaterials that could lead to techniques ... work. The key ingredients for making marble-sized pellets of ...
Cached Biology Technology:JCM Receives the Approval for its Manufacturing Environmental Assessment 2Open Ion Community Fuels Race to Win Three $1M Prizes 2Open Ion Community Fuels Race to Win Three $1M Prizes 3Open Ion Community Fuels Race to Win Three $1M Prizes 4Open Ion Community Fuels Race to Win Three $1M Prizes 5Rensselaer engineers 'cook' promising new heat-harvesting nanomaterials in microwave oven 2
(Date:8/12/2015)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is proud to announce that iMedNet ... technology platform, has led the way to significant and ... 2015.   Q2 2015 and Q1 2015 were, respectively, ... value sold in the company,s 15 year history.  In ...
(Date:8/11/2015)... -- Today, ZUK announced its Android smartphone Z1, featuring ... revenues in 2015 that relate to sales of FPC1155 for this ... 2,200 MSEK for 2015. Jörgen Lantto, CEO of FPC, ... smartphone manufacturer in China and we ... 155 for Z1 , ...
(Date:8/6/2015)... Germany , August 6, 2015 ... Instruments (SMI) shows the world,s first Eye ... on Epson,s Moverio BT-200 see-through head mounted display and ... solution, unprecedented quality and efficiency is brought to personalized ... For the first time, professionals and researchers can integrate ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... pathway that plays a critical role in the growth ... important insight into the development of the vascular system ... inhibiting the blood vessels that fuel cancers, diabetic eye ... published online on Oct. 14 in Nature Genetics. was ...
... 13, 2007Today at the Prostate Cancer Foundations Annual Scientific ... common foods such as tomatoes and fish, maintaining a ... may help prevent prostate cancer, and help men live ... men will be diagnosed with prostate cancer in their ...
... been awarded to the Intergov-ernmental Panel on Climate Change (IPCC) ... about man-made climate change, and to lay the foundations for ... In particular, the 4th United Nations Climate Report on global ... and May 2007 revealed new facts and has been a ...
Cached Biology News:Study reveals a key to blood vessel growth and possible drug target 2Study reveals a key to blood vessel growth and possible drug target 3Leading researchers to reveal comprehensive dos and don'ts for prostate cancer 2Leading researchers to reveal comprehensive dos and don'ts for prostate cancer 3Nobel Peace Prize 2007 to intergovernmental panel on climate change 2
The imaging screen-K (Kodak), tritium, is a 20 x 25 cm storage phosphor screen that is used for the quantitation and imaging of 32P, 33P, 35S, 14C, and 3H....
The filter 695RDF55 Reflect 635 for the Molecular Imager FX is a band pass filter for Cy5 and Alexa Fluor 635 dyes....
The filter 605DF50 for the Molecular Imager FX is a band pass filter for ethidium bromide, SYPRO Red, SYPRO Ruby, Alexa Fluor 532 and 546, and Cy3 dyes when using the 635 nm laser....
... The Model 175 tube gel cell is ... gels for 2-D electrophoresis applications. The upper ... OD tubes 9-23 cm long for isoelectric ... upper buffer chamber and cooling core, lower ...
Biology Products: